Henry James International Management Inc. Morpho Sys Ag Transaction History

Henry James International Management Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$8.6 - $18.18 $391,351 - $827,299	45,506 Added 105.83%	88,506 $1.61 Million
Q4 2023 Feb 06, 2024	BUY	$4.55 - $9.9 $195,650 - $425,700	43,000 New	43,000 $425,000
Q2 2022 Jul 25, 2022	SELL	$4.51 - $7.39 $180,400 - $295,600	-40,000 Closed	0 $0
Q1 2022 Apr 21, 2022	SELL	$5.87 - $9.73 $111 - $184	-19 Reduced 0.05%	40,000 $271,000
Q3 2021 Oct 19, 2021	SELL	$11.76 - $19.51 $453,030 - $751,583	-38,523 Reduced 49.05%	40,019 $471,000
Q2 2021 Jul 30, 2021	SELL	$18.95 - $23.95 $238,201 - $301,051	-12,570 Reduced 13.8%	78,542 $1.51 Million
Q1 2021 Apr 19, 2021	BUY	$21.56 - $30.66 $754,600 - $1.07 Million	35,000 Added 62.38%	91,112 $1.99 Million
Q4 2020 Jan 27, 2021	BUY	$24.81 - $30.33 $124 - $151	5 Added 0.01%	56,112 $1.59 Million
Q3 2020 Oct 07, 2020	BUY	$30.28 - $35.72 $249,416 - $294,225	8,237 Added 17.21%	56,107 $1.76 Million
Q2 2020 Jul 24, 2020	BUY	$24.08 - $33.35 $340,033 - $470,935	14,121 Added 41.84%	47,870 $1.52 Million
Q1 2020 Apr 30, 2020	SELL	$18.86 - $37.36 $2,885 - $5,716	-153 Reduced 0.45%	33,749 $829,000
Q4 2019 Jan 07, 2020	BUY	$26.07 - $36.32 $400,018 - $557,294	15,344 Added 82.68%	33,902 $1.21 Million
Q3 2019 Oct 04, 2019	SELL	$24.18 - $31.58 $2,563 - $3,347	-106 Reduced 0.57%	18,558 $510,000
Q2 2019 Jul 17, 2019	BUY	$23.24 - $26.76 $433,751 - $499,448	18,664 New	18,664 $451,000
Q1 2019 Apr 22, 2019	SELL	$22.55 - $29.84 $512,877 - $678,680	-22,744 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$21.96 - $31.02 $499,458 - $705,518	22,744 New	22,744 $575,000

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Henry James International Management Inc., based on Form 13F filings with the SEC.

Stay updated on Henry James International Management Inc. with notifications on news.